Logo_AIHTA
  • Deutsch
  • Contact
    • Imprint
      • Privacy Notice
        • Newsletter
          • Sitemap
            Menu_button
            • News
              • About us
                • Research areas
                  • Research Projects
                    • Publications
                      • Search
                        • Announcements
                          • Events
                            • Newsletter
                              • Press release on our reports
                                • Press photos
                                  Video
                                  Video: What is HTA?    
                                  • Home
                                  • News

                                  News

                                  Leiste32


                                  Welcome to the homepage of AIHTA!

                                  AIHTA is an academic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.

                                  In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.

                                  Subscribe to newsletter

                                  03-rehab

                                  Announcement

                                  Outpatient cardiac rehabilitation part VI: prospective multi-centre cohort study (comparing patients with and without phase III)

                                  In 2012, we published the study protocol of a prospective multi-centre cohort study (https://eprints.aihta.at/971/) that aimed at comparing patients who attended an outpatient phase III cardiac rehabilitation after phase II with patients who did not. We defined the mean between group difference of risk factors out of the target range at the end of the observation period as the primary outcome. Now, we report on the results: 16 months after Phase II Rehabilitation, this (adjusted) mean difference was -0,06 [-0.7;  0.6] (non-significant). Roughly spoken, about one out of twenty IG patients (6 of 100) of the sample showed one risk factor out of the target range less than a KG patient. In secondary endpoints, only the change in the exercise stress test (percental increase) and the frequency of inpatient re-rehabilitation showed a statistically significant group difference in favour of the intervention. The higher than expected drop-out should be considered when interpreting the results.

                                  Publication: LBI-HTA Project report No. 90: https://eprints.aihta.at/1101/

                                  Contact: Brigitte Piso

                                  More...

                                  Newsletter_preview

                                  Newsletter

                                  Note: this content is only available in German.

                                  Inhalt

                                  • 10 Jahre LBI-HTA: wir feiern Geburtstag!
                                  • Gesellschaftliches Engagement zur Verbesserung der Gesundheitsversorgung und Abbau gesundheitlicher Ungleichheiten
                                  • „Umschriebene Entwicklungsstörung“ motorischer Funktionen: Screening, Diagnostik und Therapieindikation
                                  • Ganzkörperkältetherapie (GKK): bei muskuloskeletalen Erkrankungen, Osteoarthritis, rheumatoider Arthritis, atopischer Dermatitis und Depression
                                  • Multiples Myelom: Kosteneffektivität von 6 neuen Behandlungsregimen
                                  • Termine
                                  • Themen-Vorschau
                                  Print Zur Druckversion...
                                  2121

                                  Announcement

                                  Horizon Scanning in Onkology - Reports

                                  We are pleased to introduce our new HSO report.

                                  DSD HSO No. 60
                                  Obinutuzumab (Gazyvaro®) in combination with bendamustine for the treatment of relapsed/refractory follicular lymphoma (FL)

                                  More...

                                  Fotolia-14918338-xl

                                  Announcement

                                  Update Re-orientation of the Austrian parent-child preventive care programme Part IX: Recommendations from evidence-based guidelines for screening measures covering early childhood (0-6 yrs.)

                                  We are pleased to present an update report covering evidence-based, international screening recommendations for children (0-6 years). Based on the extensive, original report part IX from 2013 an update was performed in terms of new or updated screening recommendations for children.

                                  Publication: LBI-HTA Project report No. 62 - Update 2016: https://eprints.aihta.at/996/

                                  Contact: Brigitte Piso

                                  More...

                                  Newsletter_preview

                                  Newsletter

                                  Note: this content is only available in German.

                                  Inhalt

                                  • EUPATI: Patienteninformation aus Pharmahand
                                  • Magnetischer Speiseröhren Ring bei gastroösophagealer Refluxkrankheit
                                  • Zungenschrittmacher bei Schlafapnoe
                                  • Einzeitiger matrix-assistierter Knorpelersatz bei chondralen Defekten im Knie
                                  • Medikamentenbeschichtete Ballonkatheter in 4 Indikationen
                                  • Radiofrequenzdenervierung bei Schmerzen im Bereich der Iliosakral- und Facettengelenke
                                  • Sondenlose Herzschrittmacher bei kardialen Arrhythmien
                                  • Klinischer Nutzen neuer Onkologika und Refundierungspolitiken
                                  • Termine
                                  • Themen-Vorschau
                                  Print Zur Druckversion...
                                  249

                                  Announcement

                                  Evaluation of individual medical procedures 2016 - Reports

                                  We are pleased to introduce our new reports.

                                  Decision Support Documents 2016:

                                  • DSD 97: Leadless pacemakers for right ventricle pacin
                                    https://eprints.aihta.at/1094/
                                  • DSD 98: Single-step scaffold-based cartilage repair in the knee
                                    https://eprints.aihta.at/1095/
                                  • DSD 99: Radiofrequency denervation for sacroiliac and facet joint pain
                                    https://eprints.aihta.at/1096/
                                  • DSD 100: Upper airway stimulation for moderate-to-severe sleep apnea
                                    https://eprints.aihta.at/1097/
                                  • DSD 101: Magnetic sphincter augmentation device (MSAD) in patients with gastroesophageal reflux disease (GERD)
                                    https://eprints.aihta.at/1098/

                                  +1 Update:

                                  • DSD 24/Update 2016:

                                    Percutaneous transluminal coronary angioplasty (PTCA) with drug-eluting balloon (DEB)
                                    https://eprints.aihta.at/1093/

                                   

                                  More...

                                  Fotolia-80437926-s

                                  Announcement

                                  Screening, diagnostics and indication for occupational therapy in children and adolescents with Developmental Coordination Disorder

                                  Developmental Coordination Disorder (DCD) is characterized by a severe developmental impair­ment of the motor coordination, which is not solely caused by mental retardation or specific neurological damage. DCD approximately affects 5 to 6% of school children. It may cause significant difficulties in activities of daily living and lead to consequences in adulthood. Children and adolescents with DCD are primarily referred to paediatric occupational therapists and physiotherapists. The report addresses the research questions, which recommendations on DCD (for screening, diagnostic testing, indication and form of therapy) are provided in evidence-based guidelines, which differentiation criteria between occupational therapy and other forms of treatment are discussed and which of the recommended tools can be introduced in Austria with regard to language (German) and standardization/ adaption (central Europe). Depending on the research question, literature was identified by a systematic and/ or manual search. A population based screening for DCD is not recom­mended due to the lack of sufficiently sensitive screening tools. For DCD diagnosis, all information sources recommend the use of standardized assessment tools. However, currently there is no gold standard available. Of 85 identified assessment tools, 12 have been translated into German and standardised/ adapted for Central Europe. Recommended interventions for children and adolescents with DCD should target the individual activity- and participation-level of the affected person. Differentiation criteria for various forms of therapy could not be identified.

                                  Publication: Decision Support Document No. 96: https://eprints.aihta.at/1092/

                                  Contact: Brigitte Piso

                                  More...

                                  Fotolia-40162114-m

                                  Announcement

                                  Drugs in Oncology: an overview of benefit and refund practices in Europe

                                  Austria belongs to those countries that adopt new cancer drugs not only early and fast, but use them also widely. In 2009, the LBI-HTA launched the program “Horizon Scanning in Oncology” (HSO) in order to enable evidence based decisions on the use of cancer drugs and estimations on implications for the health care budget in Austria. Since then numerous (n=59) early assessments of new cancer drugs were published. This review shall provide an overview of all approved cancer drugs 2009–2015 by the European Medicines Agency (EMA) and the knowledge on patient-benefit at time of approval and will analyse which policies for high-prized cancer drugs are applied in other (European) countries.

                                  At the time of approval by EMA, for 26 (23%) of 73 cancer drugs between 2009 and 2015 no information about the two endpoints overall survival (OS) and progression free survival (PFS) was available. For 37 (45%) of cancer drugs, OS was increased up to 3 months, and for 14 (13%) up to 5.8 months in relation to the comparator. The benefit assessments in various countries (Germany, England, Norway, Belgium, Netherlands, Canada) differ in the point in time carried out (before/ after approval), in methods used (only clinical benefit assessment or additional cost-effectiveness analysis), the publication of results (degree of transparency) and the binding character of recommendations (from purely informational to binding). In a comparison of national benefit assessments of cancer drugs 14 drugs in 15 indications, including also some drugs that are in the Austrian MEL-catalogue, have been assessed consistently negative (not recommended). 16 drugs in 22 indications have been assessed consistently positive (recommended). Assessments with (binding) recommendations, health economical evaluations, “Managed-Entry Agreements” and “Value-based pricing” are approaches identifying cancer drugs with the highest benefit and acceptable costs with transparent and traceable methods.

                                  Publication: Rapid Assessment No. 8: https://eprints.aihta.at/1091/

                                  Contact: Nicole Grössmann, Claudia Wild

                                  More...

                                  B0005622

                                  Announcement

                                  Opportunities and strategies to drive appropriate use of MRI in Austria. Part 2

                                  Magnetic resonance imaging (MRI) is an essential component of medical care. Currently, however, the appropriateness of diagnostic imaging is increasingly debated. In a first report we identified via database screening, literature review and interviews with stakeholders recommendations against the use of MRI and opportunities and strategies to drive appropriate imaging relevant to the Austrian context. In the second part we aim to provide additional information (on evidence base, guideline recommendations, diagnostic algorithms/decision support tools and products) on already identified recommendations regarding a set of indications selected by a working group of HVB and WKÖ.

                                  Publication: LBI-HTA Project report No. 80b: https://eprints.aihta.at/1090/

                                  Contact: Agnes Kisser

                                  More...

                                  2120

                                  Announcement

                                  Horizon Scanning in Onkology - Reports

                                  We are pleased to introduce our new HSO report.

                                  DSD HSO No. 59
                                  Afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) who are refractory to erlotinib/gefitinib and afatinib monotherapy

                                  More...

                                  « < ... 32 33 34 35 36 ... > »
                                  Displaying results 331 to 340.
                                  • News
                                    • Announcements
                                      • Events
                                        • Newsletter
                                          • Press release on our reports
                                            • Press photos
                                            • About us
                                              • Evaluation
                                                • History
                                                  • Methods
                                                    • Team
                                                      • Shareholder & organization chart
                                                        • Stakeholder involvement
                                                          • Press clippings
                                                          • Research areas
                                                            • Oncology
                                                              • High tech medicine
                                                                • Rehabilitation and occupational therapy
                                                                  • Prevention and screening
                                                                    • Psychological & psychiatric interventions
                                                                      • Health economics
                                                                        • European collaboration
                                                                          • HTA-methods & steering instruments
                                                                            • Complementary medicine
                                                                            • Research Projects
                                                                              • Synopsis of current research projects
                                                                                • Synopsis of completed research projects
                                                                                  • Decision Support Documents for the Austrian Appraisal Board
                                                                                    • HTA-Information Service Rapid Reviews
                                                                                      • Horizon Scanning in Oncology – Prioritisation of new and emerging oncologic drugs
                                                                                        • Horizon Scanning of Medicines - Reports and Fact Sheets
                                                                                          • Horizon Scanning in Oncology – support for a budget-impact-calculation
                                                                                            • Evaluation of individual medical procedures - Reports
                                                                                              • All projects in an overview
                                                                                              • Publications
                                                                                                • Repository
                                                                                                  • HTA-Newsletter
                                                                                                    • Annual Reports
                                                                                                    • Search
                                                                                                      Netzwerk
                                                                                                      • Eunethta
                                                                                                      • Ebm
                                                                                                      • Inahta
                                                                                                      • Dexhelpp
                                                                                                      Shareholder
                                                                                                      • Bmfg
                                                                                                      • Sv
                                                                                                      • Wgfond
                                                                                                      • Noe
                                                                                                      • Ooghfond
                                                                                                      • Ghls
                                                                                                      • Tirol
                                                                                                      • Vorarlberg
                                                                                                      • Kghfond
                                                                                                      • Ghpf
                                                                                                      • Burgef
                                                                                                      • Contact
                                                                                                        • Imprint
                                                                                                          • Privacy Notice
                                                                                                            • Newsletter
                                                                                                              • Sitemap
                                                                                                                © 2025 HTA Austria - Austrian Institute for Health Technology Assessment GmbH. Alle Rechte vorbehalten.
                                                                                                                • Log in